{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/37030"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/37030","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"The involvement of KAV001 in inhibition of LPS/P. gingivalis-induced cytokines","abstract":"TNF-a is an important cytokine mediator of inflammation which suggests that inhibition of TNF-a activity may provide potential for clinical application. Recent data indicated that treatment of both human and mouse cells with Kavain significantly modulates P. gingivalis- and LPS-induced TNF-α expression. In order to obtain a selective analog with optimized biological activity and structural physico-chemical properties of Kavain, Kavain analogs were designed and synthesized and found one Kavain analogue (named Kav001) that is similar to Kavain but soluble and does not induce a significant toxicity. Both studies in vitro and in vivo treatment by Kav001 showed stronger biological function as compared to Kavain. Furthermore, most mouse bone marrow macrophages up-regulated Bcl-6 while down-regulating LITAF expression after treatment with Kav001 for 36 h. Consequently, this led to an extension of macrophage pseudopods due to its immune response to P.g. infection/ LPS stimulation. we further found that Kav001 not only inhibits TNF-α, but also IL-1β, IL-6, caspase 1 and neutrophil infiltration in response to LPS. However, this phenomenon cannot be observed when macrophages were treated with LPS plus Kavain. We believe that Kav001 may mediate a novel link between Kav001 and LPS-induced inflammation and may be used as a key inhibitor to LPS-induced inflammation/inflammatory disease.","abstract_html":"TNF-a is an important cytokine mediator of inflammation which suggests that inhibition of TNF-a activity may provide potential for clinical application. Recent data indicated that treatment of both human and mouse cells with Kavain significantly modulates P. gingivalis- and LPS-induced TNF-α expression. In order to obtain a selective analog with optimized biological activity and structural physico-chemical properties of Kavain, Kavain analogs were designed and synthesized and found one Kavain analogue (named Kav001) that is similar to Kavain but soluble and does not induce a significant toxicity. Both studies in vitro and in vivo treatment by Kav001 showed stronger biological function as compared to Kavain. Furthermore, most mouse bone marrow macrophages up-regulated Bcl-6 while down-regulating LITAF expression after treatment with Kav001 for 36 h. Consequently, this led to an extension of macrophage pseudopods due to its immune response to P.g. infection/ LPS stimulation. we further found that Kav001 not only inhibits TNF-α, but also IL-1β, IL-6, caspase 1 and neutrophil infiltration in response to LPS. However, this phenomenon cannot be observed when macrophages were treated with LPS plus Kavain. We believe that Kav001 may mediate a novel link between Kav001 and LPS-induced inflammation and may be used as a key inhibitor to LPS-induced inflammation/inflammatory disease.","abstract_has_math":false,"creators":["Alasiri, Mansour"],"institution":"Boston University","degree_name":"Doctor of Science in Dentistry","degree_level":"doctoral","degree_discipline":"Periodontology","degree_department":null,"school":null,"contributors":[],"advisors":["Tang, Xiaoren"],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019","date_published":"2019","updated_at":"2026-11-18T20:05:48Z","subjects":["Dentistry","Cytokines","KAV001","Kavain","P. gingivalis","TNF-a"],"languages":["en_US"],"rights":["Attribution-NonCommercial-NoDerivatives 4.0 International"],"rights_urls":["http://creativecommons.org/licenses/by-nc-nd/4.0/"],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/37030","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/37030","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F37030","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Tang, Xiaoren"]},{"key":"dc:creator","label":"Author","values":["Alasiri, Mansour"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2019-08-07T14:10:23Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2019-08-07T14:10:23Z"]},{"key":"dc:date.issued","label":"Date","values":["2019"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2019-07-02T19:04:22Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Periodontology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Science in Dentistry"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Dentistry","Cytokines","KAV001","Kavain","P. gingivalis","TNF-a"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution-NonCommercial-NoDerivatives 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://creativecommons.org/licenses/by-nc-nd/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/37030"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["TNF-a is an important cytokine mediator of inflammation which suggests that inhibition of TNF-a activity may provide potential for clinical application. Recent data indicated that treatment of both human and mouse cells with Kavain significantly modulates P. gingivalis- and LPS-induced TNF-α expression. In order to obtain a selective analog with optimized biological activity and structural physico-chemical properties of Kavain, Kavain analogs were designed and synthesized and found one Kavain analogue (named Kav001) that is similar to Kavain but soluble and does not induce a significant toxicity. Both studies in vitro and in vivo treatment by Kav001 showed stronger biological function as compared to Kavain. Furthermore, most mouse bone marrow macrophages up-regulated Bcl-6 while down-regulating LITAF expression after treatment with Kav001 for 36 h. Consequently, this led to an extension of macrophage pseudopods due to its immune response to P.g. infection/ LPS stimulation. we further found that Kav001 not only inhibits TNF-α, but also IL-1β, IL-6, caspase 1 and neutrophil infiltration in response to LPS. However, this phenomenon cannot be observed when macrophages were treated with LPS plus Kavain. We believe that Kav001 may mediate a novel link between Kav001 and LPS-induced inflammation and may be used as a key inhibitor to LPS-induced inflammation/inflammatory disease."]},{"key":"dc:title","label":"Title","values":["The involvement of KAV001 in inhibition of LPS/P. gingivalis-induced cytokines"]}]}],"canonical_facts":{"dc:contributor.advisor":["Tang, Xiaoren"],"dc:creator":["Alasiri, Mansour"],"dc:date.accessioned":["2019-08-07T14:10:23Z"],"dc:date.available":["2019-08-07T14:10:23Z"],"dc:date.issued":["2019"],"dc:date.updated":["2019-07-02T19:04:22Z"],"dc:description.abstract":["TNF-a is an important cytokine mediator of inflammation which suggests that inhibition of TNF-a activity may provide potential for clinical application. Recent data indicated that treatment of both human and mouse cells with Kavain significantly modulates P. gingivalis- and LPS-induced TNF-α expression. In order to obtain a selective analog with optimized biological activity and structural physico-chemical properties of Kavain, Kavain analogs were designed and synthesized and found one Kavain analogue (named Kav001) that is similar to Kavain but soluble and does not induce a significant toxicity. Both studies in vitro and in vivo treatment by Kav001 showed stronger biological function as compared to Kavain. Furthermore, most mouse bone marrow macrophages up-regulated Bcl-6 while down-regulating LITAF expression after treatment with Kav001 for 36 h. Consequently, this led to an extension of macrophage pseudopods due to its immune response to P.g. infection/ LPS stimulation. we further found that Kav001 not only inhibits TNF-α, but also IL-1β, IL-6, caspase 1 and neutrophil infiltration in response to LPS. However, this phenomenon cannot be observed when macrophages were treated with LPS plus Kavain. We believe that Kav001 may mediate a novel link between Kav001 and LPS-induced inflammation and may be used as a key inhibitor to LPS-induced inflammation/inflammatory disease."],"dc:identifier.uri":["https://hdl.handle.net/2144/37030"],"dc:language.iso":["en_US"],"dc:rights":["Attribution-NonCommercial-NoDerivatives 4.0 International"],"dc:rights.uri":["http://creativecommons.org/licenses/by-nc-nd/4.0/"],"dc:subject":["Dentistry","Cytokines","KAV001","Kavain","P. gingivalis","TNF-a"],"dc:title":["The involvement of KAV001 in inhibition of LPS/P. gingivalis-induced cytokines"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Periodontology"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Science in Dentistry"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:05:48Z"}